Appointment of Stacy Price as Chief Technology Officer strengthens Upstream Bio's leadership team with her extensive experience in technical operations and product development in the biotechnology ...

Upstream Bio completed Phase 2 trial enrollment for verekitug and raised $293 million in an IPO, funding operations through 2027. Upstream Bio, Inc. announced the completion of patient enrollment in ...

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 – – Top-line data from Phase 2 clinical trial ...

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...

Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and inflammatory diseases, such as asthma, where disruption of TSLP signaling has ...

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

) has been revised to $51.00 / share. This is a decrease of 18.03% from the prior estimate of $62.22 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...